Neuronetics (STIM) Common Equity (2016 - 2026)

Neuronetics (STIM) has 11 years of Common Equity data on file, last reported at $13.3 million in Q1 2026.

• Common Equity for Q1 2026 came in at $13.3 million, down 66.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.3 million (down 66.44% YoY), and the FY2025 annual result was $22.4 million, down 29.63% from the prior year.
• Common Equity retreated to $13.3 million in Q1 2026 per STIM's latest filing, from $22.4 million in the prior quarter.
• Over five years, Common Equity peaked at $76.6 million in Q1 2022 and troughed at $9.4 million in Q3 2024.
• A 5-year average of $38.7 million and a median of $34.2 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2024 and 2025: Common Equity tumbled 75.27% in 2024, then soared 234.29% in 2025.
• A 5-year view of Common Equity shows it stood at $57.1 million in 2022, then sank by 40.08% to $34.2 million in 2023, then slipped by 6.99% to $31.8 million in 2024, then slipped by 29.63% to $22.4 million in 2025, then slumped by 40.72% to $13.3 million in 2026.
• Business Quant data shows STIM's Common Equity at $13.3 million in Q1 2026, $22.4 million in Q4 2025, and $31.4 million in Q3 2025.